Royalty Pharma plc announced on April 8, 2025, the appointment of Vlad Coric, M.D., to the company’s Board of Directors, effective immediately. Dr. Coric currently serves as the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on neuroscience, immunology, and oncology.
Dr. Coric brings over 20 years of experience in drug discovery and clinical development, having successfully led Biohaven through the FDA approval and launch of Nurtec ODT for migraine. His expertise spans multiple therapeutic areas within the pharmaceutical industry.
This appointment is expected to strengthen Royalty Pharma's Board with Dr. Coric's entrepreneurial approach, leadership skills, and notable experience in the royalty funding space, further supporting the company's position as a leading partner in funding life sciences innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.